المؤلفون: Naboka YL; Rostov State Medical University, Rostov-on-Don, Russia., Gudima IA; Rostov State Medical University, Rostov-on-Don, Russia., Mordanov SV; Rostov State Medical University, Rostov-on-Don, Russia., Krakhotkin DV; Rostov State Medical University, Rostov-on-Don, Russia., Ilyash AV; Rostov State Medical University, Rostov-on-Don, Russia., Kogan MI; Rostov State Medical University, Rostov-on-Don, Russia., Ibishev KS; Rostov State Medical University, Rostov-on-Don, Russia.

المصدر: Urologiia (Moscow, Russia : 1999) [Urologiia] 2020 Mar (1), pp. 12-18.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Medit︠s︡ina Country of Publication: Russia (Federation) NLM ID: 100900900 Publication Model: Print Cited Medium: Print ISSN: 1728-2985 (Print) Linking ISSN: 17282985 NLM ISO Abbreviation: Urologiia Subsets: MEDLINE

مواضيع طبية MeSH: Microbiota* , Urinary Tract Infections*, Adult ; Bacteria ; Escherichia coli ; Female ; Humans ; Male ; Young Adult

المؤلفون: Lavrov AV; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522. alexandervlavrov@gmail.com.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education 'Russian National Research Medical University named after N.I. Pirogov' of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997. alexandervlavrov@gmail.com., Chelysheva EY; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Adilgereeva EP; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Shukhov OA; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Smirnikhina SA; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Kochergin-Nikitsky KS; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Yakushina VD; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522., Tsaur GA; Regional Children Hospital 1, S. Deryabinoy str., 32, Ekaterinburg, Russian Federation, 620149.; Research Institute of Medical Cell Technologies, Soboleva str., 25, Ekaterinburg, Russian Federation, 620905.; Federal State Budgetary Educational Institution of Higher Education, Urals State Medical University of the Ministry of Healthcare of the Russian Federation, Repina str., 3, Ekaterinburg, Russian Federation, 620028., Mordanov SV; Laboratory of Medical Genetics, The Rostov State Medical University, Nahichevansky av., 29, Rostov-on-Don, Russian Federation, 344022., Turkina AG; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167., Kutsev SI; Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education 'Russian National Research Medical University named after N.I. Pirogov' of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997.

المصدر: BMC medical genomics [BMC Med Genomics] 2019 Mar 13; Vol. 12 (Suppl 2), pp. 37. Date of Electronic Publication: 2019 Mar 13.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101319628 Publication Model: Electronic Cited Medium: Internet ISSN: 1755-8794 (Electronic) Linking ISSN: 17558794 NLM ISO Abbreviation: BMC Med Genomics Subsets: MEDLINE

مواضيع طبية MeSH: Exome* , Transcriptome*, Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy , MicroRNAs/*metabolism , Protein Kinase Inhibitors/*therapeutic use, Adult ; Aged ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Female ; Genotype ; Humans ; Imatinib Mesylate/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Male ; Middle Aged ; Polymorphism, Genetic ; Prognosis ; Treatment Outcome ; Young Adult

المؤلفون: Lavrov AV; Laboratory of Mutagenesis, Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, Russian Federation.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education Russian National Research Medical University named after N.I. Pirogov of Ministry of Health of the Russian Federation, Moscow, Russian Federation., Ustaeva OA; Laboratory of Medical Genetics, The Rostov State Medical University, Rostov-on-Don, Russian Federation., Adilgereeva EP; Laboratory of Mutagenesis, Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, Russian Federation., Smirnikhina SA; Laboratory of Mutagenesis, Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, Russian Federation., Chelysheva EY; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., Shukhov OA; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., Shatokhin YV; Laboratory of Medical Genetics, The Rostov State Medical University, Rostov-on-Don, Russian Federation., Mordanov SV; Laboratory of Medical Genetics, The Rostov State Medical University, Rostov-on-Don, Russian Federation., Turkina AG; Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., Kutsev SI; Laboratory of Mutagenesis, Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, Russian Federation.; Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education Russian National Research Medical University named after N.I. Pirogov of Ministry of Health of the Russian Federation, Moscow, Russian Federation.

المصدر: PloS one [PLoS One] 2017 Sep 13; Vol. 12 (9), pp. e0182901. Date of Electronic Publication: 2017 Sep 13 (Print Publication: 2017).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: DNA Copy Number Variations*, Cytochromes/*genetics , Drug Resistance, Neoplasm/*genetics , Glutathione Transferase/*genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics , Protein Kinase Inhibitors/*therapeutic use, Adult ; Aged ; Biomarkers, Tumor/genetics ; Case-Control Studies ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Male ; Middle Aged ; Prognosis ; Treatment Outcome ; Young Adult